Regeneron Pharmaceuticals Stock: Is Wall Street Bullish or Bearish?

With a market cap of $63.5 billion, Regeneron Pharmaceuticals, Inc. (REGN) is a fully integrated biotechnology company that discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company’s products include EYLEA injection, Dupixent Injection, Libtayo Injection, Praluent Injection, Kevzara Injection, and others.

Shares of REGN have significantly underperformed the broader market over the past 52 weeks. REGN has dropped 40% over this time frame, while the broader S&P 500 Index ($SPX) has gained 10.2%. Moreover, shares of REGN are down 17.4% on a YTD basis, compared to SPX’s 1.3% drop.